Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NGNE

Neurogene Inc

Dec 26 • 04:00PM ET

24.10

Dollar change +1.48
Percentage change 6.54	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX RARE BLUE PRTA PTCT AXSM ACAD BTAI FATE RNA

| Held by: VTI IWM VXF DWAS IBB VTWO IWO IWN VFMO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.49	Insider Own	22.93%	Shs Outstand	20.98M	Perf Week	10.60%
Market Cap	505.61M	Forward P/E	-	EPS next Y	-4.22	Insider Trans	2.56%	Shs Float	16.17M	Perf Month	8.00%
Income	-71.13M	PEG	-	EPS next Q	-1.13	Inst Own	62.08%	Short Float	9.90%	Perf Quarter	-38.49%
Sales	0.93M	P/S	543.67	EPS this Y	-245.34%	Inst Trans	46.44%	Short Ratio	4.29	Perf Half Y	-30.79%
Book/sh	10.56	P/B	2.28	EPS next Y	0.94%	ROA	-56.07%	Short Interest	1.60M	Perf Year	52.44%
Cash/sh	6.62	P/C	3.64	EPS next 5Y	25.10%	ROE	-66.90%	52W Range	14.44 - 74.49	Perf YTD	24.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.09%	ROI	-48.18%	52W High	-67.65%	Beta	1.12
Dividend TTM	-	Quick Ratio	9.09	Sales past 5Y	-20.00%	Gross Margin	-370.16%	52W Low	66.90%	ATR (14)	2.89
Dividend Ex-Date	-	Current Ratio	9.09	EPS Y/Y TTM	-342.14%	Oper. Margin	-10552.11%	RSI (14)	44.24	Volatility	7.14% 9.16%
Employees	91	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-7689.95%	Recom	1.14	Target Price	52.80
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-192.49%	Payout	-	Rel Volume	0.58	Prev Close	22.62
Sales Surprise	-	EPS Surprise	2.59%	Sales Q/Q	-	Earnings	Nov 18 AMC	Avg Volume	372.83K	Price	24.10
SMA20	3.32%	SMA50	-32.84%	SMA200	-36.17%	Trades		Volume	217,184	Change	6.54%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$65
Jun-11-24	Initiated	Robert W. Baird	Outperform	$54
Apr-29-24	Initiated	Leerink Partners	Outperform	$46
Mar-21-24	Initiated	William Blair	Outperform	$61
Jan-08-24	Initiated	H.C. Wainwright	Buy	$45
Jan-05-24	Initiated	Stifel	Buy	$31
Jan-04-24	Initiated	TD Cowen	Outperform

Nov-18-24 05:25PM	Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire) -42.58% -13.07%
04:14PM	How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week (Investor's Business Daily)
09:48AM	Neurogene Down 36% Extends Losses After Side Effect Derails Its Rett Syndrome Drug (Investor's Business Daily)
06:45AM	Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
Nov-12-24 04:10PM	Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal (Investor's Business Daily) -44.08%
10:18AM	Loading…
10:18AM	Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect (Investor's Business Daily)
06:58AM	Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data (GuruFocus.com)
Nov-11-24 04:01PM	Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
Nov-05-24 07:54AM	Neurogene Secures $200M for Genetic Therapy Development (TipRanks)
Nov-04-24 07:30AM	Neurogene Announces Oversubscribed $200 Million Private Placement (Business Wire) +43.26%
Oct-21-24 07:30AM	Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Aug-09-24 02:52PM	NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 (InvestorPlace)
07:30AM	Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
Aug-07-24 07:30AM	Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome (Business Wire)
Jul-02-24 07:30AM	Neurogene to Participate in BMO Genetic Medicines Summit (Business Wire) -5.32%
07:30AM	Loading…
Jul-01-24 07:30AM	Neurogene Announces Addition to Russell 3000 Index (Business Wire) +11.62%
Jun-19-24 09:23AM	Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation (Insider Monkey)
Jun-18-24 09:26AM	Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire) -24.20%
Jun-05-24 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
Jun-03-24 07:30AM	Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program (Business Wire)
May-10-24 01:54PM	NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
May-07-24 06:19AM	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting (Business Wire)
Apr-22-24 04:36PM	Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM	Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-18-24 04:14PM	Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire) +20.00%
Mar-04-24 07:30AM	Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
Feb-29-24 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM	Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
Jan-05-24 07:00AM	Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
07:00AM	Loading…
Dec-19-23 07:00AM	Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Samsara BioCapital GP, LLC	10% Owner	Nov 26 '24	Buy	25.83	48,770	1,259,623	1,717,127	Nov 27 04:39 PM
Cvijic Christine Mikail	President and CFO	Nov 22 '24	Buy	20.48	24,000	491,400	76,844	Nov 25 09:29 PM
McMinn Rachel	Chief Executive Officer	Nov 22 '24	Buy	20.40	47,500	969,000	1,297,859	Nov 25 09:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGNE

Neurogene Inc

Upgrade your FINVIZ experience